

1 **SARS-CoV-2 infects, replicates, elevates angiotensin II and activates immune cells**
2 **in human testes**

3 **Authors:**

4 Guilherme M.J. Costa^{1*}; Samyra M.S.N. Lacerda¹; André F.A. Figueiredo¹; Natália T.
5 Wnuk¹; Marcos R. G. Brener¹; Gabriel H. Campolina-Silva¹; Andrea Kauffmann-Zeh²;
6 Lucila GG Pacifico²; Alice F. Versiani^{3,4}; Lídia M. Andrade¹; Maísa M. Antunes¹;
7 Fernanda R. Souza¹; Geovanni D. Cassali¹; André L. Caldeira-Brant^{1,5}; Hélio Chiarini-
8 Garcia¹; Vivian V. Costa¹; Flavio G. da Fonseca¹, Maurício L. Nogueira^{3,4}; Guilherme R.
9 F. Campos³; Lucas M. Kangussu¹; Estefânia M. N. Martins⁶; Loudiana M. Antonio¹;
10 Cintia Bittar⁷; Paula Rahal⁷; Renato S. Aguiar¹; Bárbara P. Mendes²; Marcela S.
11 Procópio²; Thiago P. Furtado²; Yuri L Guimaraes^{2,8}; Gustavo B Menezes¹; Ana Martinez-
12 Marchal⁵; Miguel Brieno-Enriquez⁵; Kyle E. Orwig⁵; Marcelo H. Furtado^{2,8}

13 **Filiation:**

14 1- Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil
15 2- Clínica MF Fertilidade Masculina, Belo Horizonte, MG, Brazil.
16 3- Faculdade de Medicina de São Jose do Rio Preto, São Jose do Rio Preto, SP, Brazil.
17 4- Department of Pathology, University of Texas Medical Branch, Galveston, Texas,
18 U.S.A.
19 5- Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Women's
20 Research Institute, University of Pittsburgh School of Medicine, Pittsburgh, USA
21 6 - Centro de Desenvolvimento da Tecnologia Nuclear-CDTN/CNEN, Belo Horizonte,
22 MG, Brazil.
23 7- Universidade Estadual Paulista, São José do Rio Preto, SP, Brazil.
24 8- Departamentos de Urologia e de Reprodução Humana da Rede Mater Dei de Saúde,
25 Belo Horizonte, MG, Brazil.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Corresponding author:**

27 **Guilherme M J Costa – gmjc@ufmg.br**

28

29 **ABSTRACT**

30 **Although much has been published since the first cases of COVID-19, there remain**
31 **unanswered questions regarding SARS-CoV-2 impact on testes and the potential**
32 **consequences for reproductive health. We investigated testicular alterations in**
33 **deceased COVID-19-patients, the precise location of the virus, its replicative**
34 **activity, and the molecules involved in the pathogenesis. We found that SARS-CoV-**
35 **2 testicular tropism is higher than previously thought and that reliable viral**
36 **detection in the testis requires sensitive nanosensing or RT-qPCR using a specific**
37 **methodology. Macrophages and spermatogonial cells are the main SARS-CoV-2**
38 **lodging sites and where new virions form inside the Endoplasmic Reticulum Golgi**
39 **Intermediate Complex. Moreover, we showed infiltrative infected monocytes**
40 **migrating into the testicular parenchyma. SARS-CoV-2 maintains its replicative**
41 **and infective abilities long after the patient’s infection, suggesting that the testes may**
42 **serve as a viral sanctuary. Further, infected testes show thickening of the tunica**
43 **propria, germ cell apoptosis, Sertoli cell barrier loss, evident hemorrhage,**
44 **angiogenesis, Leydig cell inhibition, inflammation, and fibrosis. Finally, our findings**
45 **indicate that high angiotensin II levels and activation of mast cells and macrophages**
46 **may be critical for testicular pathogenesis. Importantly, our data suggest that**
47 **patients who become critically ill exhibit severe damages and may harbor the active**
48 **virus in testes.**

49

50

51 INTRODUCTION

52 Since the testis displays one of the highest expressions of Angiotensin Converting
53 Enzyme 2 (ACE2) receptors, which mediate the cellular entry of SARS-CoV-2, and
54 current data suggest that men are more affected than women(1), deep testicular
55 evaluations of patients affected by COVID-19 is imperative. Previous studies present
56 discordant results concerning SARS-CoV-2 detection in testicular parenchyma through
57 RT-PCR (2–5) and the extent of testicular damage caused by the virus(5). Moreover, many
58 questions about viral infection remain unexplored, such as the viral replication, route of
59 infection, and the identity of infected cells.

60 Although some testicular alterations promoted by SARS-CoV-2 infection were
61 previously demonstrated(2–5), the players of testicular pathogenesis in COVID-19
62 remain unknown. Thus, studying the cellular, enzymatic, hormonal, and critical gene
63 alterations in the testes of COVID-19 patients should contribute to a better understanding
64 of SARS-CoV-2 biology and its possible impact on testes and male fertility. Recently,
65 Edenfield and Easley(6) published a perspective article in Nature Reviews Urology
66 urging the need to unveil the potential mechanisms involving SARS-CoV-2's entry and
67 pathophysiological effects on affected subjects.

68 We used different methods to detect SARS-CoV-2 in the testis parenchyma of
69 patients deceased with COVID-19 and investigated the virus infective and replicative
70 capacities. We also revealed the cellular and molecular alterations in human testicular
71 pathophysiology and correlated the findings with the patients' clinical data, unveiling
72 potential mechanisms underlying the observed alterations

73

74 MATERIAL AND METHODS

75 COVID-19 PATIENTS

76 In 2021, we enrolled 11 non-vaccinated male patients deceased from COVID-19
77 complications, confirmed by SARS-CoV-2 RT-qPCR performed during their hospital
78 stay, initially admitted in hospitals of Belo Horizonte, Brazil. All 11 patients were
79 admitted to the ICU due to severe pulmonary symptoms (Table 1). The standard treatment
80 at ICU included antibiotics, antimycotics, sedatives, muscular relaxants, analgesics,
81 antihypertensives, inotropes, vasopressors agents, invasive mechanical ventilation, and
82 hemodialysis. The Research Ethics Committee of the Mater Dei Hospital and the National
83 Research Ethics Committee (CONEP) approved this investigation under the number
84 CAAE: 30999320.1.0000.5128.

85 Postmortem collection of both testicles was performed after a legally responsible
86 family member signed an informed consent document. Testicles were collected through
87 an incision on the median raphe of the scrotum. Two authors (MHF and YLG) collected
88 all testicles no later than three hours after the patients' death. To perform viral and
89 testicular genetic studies, fragments of testicular parenchyma were sampled and
90 immersed into RNAlater® solution (Sigma-Aldrich). To investigate the viral replicative
91 activity and testosterone and angiotensin levels, testis fragments were also sampled and
92 then snap-frozen in liquid nitrogen. The remaining testicular halves were immersed in
93 different fixatives, such as Paraformaldehyde 4%, Bouin, Methacarn, and Glutaraldehyde
94 4%. Testis fragments were embedded in Methacrylate, Epon 812 resin, and Paraplast®
95 for histological, transmission electron microscopy (TEM), and immunohistochemistry
96 analyses.

97

98 **CONTROL PATIENTS**

99 The Control group was composed of six patients who underwent orchiectomy due to
100 prostate cancer suspicion. These patients did not go through any treatment at the time of

101 orchietomy. Moreover, they exhibited normal spermatogenesis in seminiferous tubules.
102 The age and hormonal levels of these patients are presented in Supplemental Table 1.
103 Testicular fragments were obtained after the study was approved by the Ethics Committee
104 in Research of the Universidade Federal de Minas Gerais COEP/UFMG (COEP ETIC
105 n°117/07). All patients signed the informed consent. Testicular samples were placed in
106 liquid nitrogen, embedded in methacrylate, Epon, paraplant®, and conserved in
107 RNAlater. These samples were used for TEM, histological, hormonal, and molecular
108 analyses. The mean age of patients was 58 years old, ranging from 46 to 65 years old.

109

110 **DETECTION OF SARS-CoV-2 IN TESTIS TISSUE**

111 **GENETIC ASSAYS**

112 **SARS-CoV-2 detection using standard RT-qPCR**

113 RNA of samples was extracted according to the protocol specified by the extraction kit.
114 The following kit was used: QIAamp® Viral RNA Mini Kit. The samples were stored in
115 an ultra-freezer at -80 °C for preservation. The collected samples were tested for the
116 presence of SARS-CoV-2 viral RNA by RT-qPCR with primers to amplify the envelope
117 (E) gene in addition to an endogenous control, the human transcript of the gene for
118 RNaseP (RNP)(7). Samples were considered positives with a cycle threshold (CT) \leq 40.

119

120 **RT-qPCR using specific viral primers**

121 Testes samples were macerated and submitted to RNA extraction using the Viral RNA
122 Kit (Zymo Research, USA), following the manufacturer's protocol. A two-step RT-qPCR
123 approach was performed to optimize the detection of the viral RNA in the tissue samples
124 and to avoid the possible influence of host cellular RNA. The obtained RNA was first
125 submitted to cDNA synthesis using the CDC's SARS-CoV-2 specific reverse primer

126 2019-nCoV_N1-R (TCT GGT TAC TGC CAG TTG AAT CTG) and the SuperScript™
127 III First-Strand Synthesis System (Invitrogen, Brazil).
128 The viral cDNAs were then amplified in a qPCR reaction using the GoTaq qPCR Master
129 Mix (Promega, USA). We used both N1 primers from CDC's SARS-CoV-2 detection
130 protocol (2019-nCoV_N1-F: GAC CCC AAA ATC AGC GAA AT; 2019-nCoV_N1-R:
131 TCT GGT TAC TGC CAG TTG AAT CTG) and followed the cycling recommendation
132 indicated by the enzyme's supplier in a QuantStudio 3 Real-Time PCR System (Applied
133 Biosystems, USA). To normalize the results, the same process was performed to amplify
134 the human β -actin control.

135

136 **PROTEIN ASSAYS**

137 **Nanosensor**

138 Gold nanorods (GNRs) were synthesized by the seed-mediated growth method as
139 previously described(8). The nanoparticles contained an average aspect ratio of 10 x 38
140 nm and a light absorbance peak of 713nm. They were covalently functionalized with the
141 polyclonal antibody anti-Spike protein (Rhea Biotech, Brazil) and a polyclonal antibody
142 anti-Nucleocapsid protein (CTVacinas, Brazil) through a carbodiimide-activated
143 amidation reaction. The binding between the gold surface and the antibodies was
144 mediated by adding a capping layer formed by α -lipoic acid. A 2mM α -lipoic acid
145 solution (LA; Sigma Aldrich, USA) in ethanol was added to the GNR suspension
146 (0.039mg/mL). These suspensions were exposed to an ultrasonic bath (UNIQUE model
147 U5C1850, 154W, 25KHz) at 55°C for 30 min. The suspension was sonicated again for 2
148 h at 30 °C and left to rest overnight at RT to stabilize the interaction. GNRs were then
149 centrifuged at 5600g for 10 min and suspended in an aqueous solution. The GNR-LA
150 complexes were kept at 4°C in the dark. Next, the modified GNRs were re-dispersed in a

151 10 mM phosphate buffer containing 16 mM EDAC and 4 mM sulfo-NHS (30 min in an
152 ice-bath under sonication). After another centrifugation step, GNR-LA suspensions were
153 blocked with poly (ethylene glycol)-thiolate (5kD mPEG-SH, 10⁻⁴ mM, from Nanocs)
154 for 10 min in an ice bath, under stirring (Supplemental Fig.1a-b).

155 TEM images of the nanosensors were obtained on a 120 kV FEI Technai G2-12 (Spirit
156 BioTwin, USA) microscope (Supplemental Fig.1c). Samples were directly dripped onto
157 a holey carbon film supported on a copper grid (400 mesh) (Pelco®, USA) without any
158 further processing. Zeta potential was obtained with a Zetasizer Nano ZS90 analyzer from
159 Malvern at an angle of 173° at RT, as previously described(9–11). Nanoparticle's size and
160 zeta potential were measured simultaneously three times and in triplicate (Supplemental
161 Fig.1d-e).

162 Samples' labeling and measurements were previously described^{3,4}. Briefly, GNR-S were
163 incubated with 1mg/mL of anti-S protein polyclonal antibody (Rhea Biotech, Brazil).
164 Next, the samples were labeled with goat anti-rabbit IgG-CFL 488, 100µg/mL λ_{em} :
165 488nm, λ_{em} : 520nm (Santa Cruz Biotechnology, USA) (Supplemental Fig1.f). For GNR-
166 N, samples were incubated with 10µg of a polyclonal antibody anti-protein N for 60 min
167 under axial shaking. Unbound antibodies were blocked with BSA (1%) for 30 min. Next,
168 samples were labeled with Alexa Fluor® 546 goat anti-rabbit IgG H & L, 5µg/mL λ_{em} :
169 540nm, λ_{em} : 585nm (Invitrogen, USA) and incubated under continuous shaking in the
170 dark and at RT for 30 min (Supplemental Fig.1g). Samples were measured using the
171 spectrophotometer Varioskan Flash spectral scanning multimode reader (Thermo
172 Scientific, USA).

173 To determine the concentration of antibodies in the LSPR-nanosensor, an antibody curve
174 was carried out ranging from 0.25µg to 10µg for anti-S and anti-N proteins, respectively
175 (Supplemental Fig.1h-l). The concentration chosen was 0.5 µg for both GNR-S and GNR-

176 N nanosensors. Afterward, the nanosensors were exposed to purified S- and N-proteins,
177 ranging from 10 μ g to 10fg, and their binding affinity was assessed by UV-Vis
178 spectroscopy (Thermo Scientific, USA).
179 Finally, the GNR-S and GNR-N nanosensors were exposed to macerated testes samples
180 (obtained from the 11 patients' with COVID-19), diluted in PBS-1X, for 30min at 4°C
181 under sonication, and their respective LSPR were measured using optical plates (Costar,
182 USA), by UV-Vis spectroscopy (Thermo Scientific, USA). Spectra analyses were
183 performed using OriginPro version 9.0. We normalized and smoothed the curves and
184 measured the biosensing event through the X-axis intercept of the derivative of the
185 Gaussian peak for each patient. We compared the COVID-19 patient curves to the GNR
186 and negative control patient curves (Supplemental Fig.1 m-q). We focused on the redshift
187 that occurred at point zero (derivative axis) of the longitudinal peak. In this analysis, 5nm
188 or below shifts were not considered significant.

189

190 **Immunofluorescence against Spike protein**

191 Immunofluorescence was performed using a validated primary anti-S protein
192 antibody(12) (Rhea Biotech; IM-0828) to detect and corroborate the viral presence in the
193 testicular parenchyma (Supplemental Table 2). Reactions were visualized using Alexa-
194 488 (1:100 dilution; Thermo Fisher Scientific, USA) conjugated secondary antibody, and
195 images were acquired using a Nikon Eclipse Ti fluorescence microscope. As controls, we
196 performed three different assays: 1) we used the testes of Controls (prostate cancer
197 patients); 2) we omitted the primary antibody in testes of COVID-19 patients; and 3) we
198 performed a negative control antigen, incubating the primary antibody with purified Spike
199 protein (1:10; donated by CT-Vacinas-UFMG) before the IF assay (Supplemental
200 Fig.2m-p).

201

202 **SARS-CoV-2 ACTIVITY AND REPLICATION**

203 ***in vitro* isolation of SARS-CoV-2**

204 Viral isolation was performed to verify if the virus detected in the testes' samples were
205 infective. In a biosafety level 3 (BSL-3) laboratory, a sample of the COVID-19 patient
206 #1 was macerated using the L-Beader 6 tissue disruptor (Loccus, Brazil) and magnetic
207 beads. We chose this patient because he presented the earliest CT for SARS-CoV-2 gene
208 N in the RT-qPCR (with specific viral primers). The disrupted sample was resuspended
209 in 500 µl of PBS 1x, and 200 µL was used for infection *in vitro*. Vero CCL-81 cells were
210 seeded in a T25 flask until complete confluence was achieved. Culture media was
211 discarded, and cells were incubated with 200 µL of the disrupted sample for 1 h, at 37°C
212 and 5% CO₂, with periodic homogenization.

213 After incubation, 5 mL of fresh DMEM was added, and cells were maintained (at 37°C
214 and 5% CO₂) for 72 h or until cytopathic effects. In parallel, the same process was
215 performed on a 24-well plate. The results were compared with a Mock-infection (Control)
216 in both cases. After this period, supernatant from the T25 flask was collected for viral
217 genome detection by RT-qPCR. Additionally, cells from the 24-well plate were incubated
218 with paraformaldehyde 4% for 20 min (Synth, Brazil) to perform the
219 immunocytochemistry analyses.

220

221 **Viral detection in Vero cell culture**

222 To confirm the isolation of SARS-CoV-2, we extracted the total RNA from the
223 supernatant using a TRIzol extraction protocol. In a 1.5mL tube, 300 µL of supernatant
224 was homogenized with 200 µL of TRIzol (Thermo Fisher Scientific, USA) and incubated
225 for 20 min to guarantee viral inactivation. RNA separation, precipitation, and elution were

226 performed by a chloroform-isopropanol protocol, according to the TRIzol manufacturer's
227 instructions. According to the kit's instructions, total RNA was submitted to RT-qPCR
228 using the Allplex™ 2019-nCoV Assay (Seegene, Brazil). Cycling steps were performed
229 in a QuantStudio™ 3 Real-Time PCR System (Applied Biosystems, USA).

230

231 **Immunohistochemistry in Vero cells**

232 To confirm viral isolation from the patients' testes, we performed an
233 immunohistochemistry assay using the anti-S commercial antibody (Rhea Biotech,
234 Brazil). After fixation, the plates were washed with PBS 1X and blocked with a PBS
235 solution containing 3% FBS for 15 min. Then, the cells were incubated overnight with
236 the anti-S antibody (dilution 1:500) at RT.

237 The cells were also incubated with an anti-rabbit IgG antibody conjugated to horseradish
238 peroxidase (Promega, USA), diluted at 1:2500 at RT for 60 min. Immunoassay was
239 revealed using the KPL TrueBlue Peroxidase Substrate (SeraCare, USA) for 10 min at
240 RT, under gentle stir.

241

242 **HISTOMORPHOMETRIC ANALYSIS**

243 All testicular slides were scanned using the Panoramic MIDI II slide scanner
244 (3DHISTECH, Hungary). The histomorphometric analyses were performed using the
245 CaseViewer software (3DHISTECH, Hungary) and the Image J v.1.45s software (Image
246 Processing and Analysis, in Java, USA).

247

248 **Seminiferous epithelium cell composition**

249 To describe the seminiferous epithelium integrity, at least 50 seminiferous tubules cross-
250 sections were evaluated and classified according to the presence of the most differentiated

251 germ cell type. The cross-sections were then classified as 1) containing all germ cell
252 layers; 2) containing spermatogonia and spermatocytes; 3) containing only
253 spermatogonia, and 4) degenerating/Sertoli cell-only seminiferous tubules. After this
254 blinded analysis, to understand the evolution of testicular pathology, we examined the
255 clinical data of COVID-19 patients. These patients were classified into three phases
256 according to the severity of the damages inflicted to the seminiferous epithelium. The
257 results are presented as the percentage of seminiferous tubules in each category.

258

259 **Seminiferous tubule measurements**

260 Seminiferous tubules were analyzed using computer-assisted image analysis of 30
261 randomly chosen seminiferous tubules cross-sections per donor. To determine the
262 seminiferous tubule diameter and tunica propria width, the measurements were taken at
263 400x magnification, and the results were expressed in μm .

264

265 **Leydig cell volume density**

266 The volume densities (%) of testicular tissue components were obtained after counting
267 7200 points over testis parenchyma. The intersections that coincided LCs were counted
268 in 15 randomly chosen fields by horizontal scanning of the histological sections at 200x
269 magnification(13).

270

271 **Hemorrhagic scores**

272 As red cell bleeding was a common finding, this pathology was measured in four scores,
273 as follows:

- 274 1. Patients who presented many red blood cells inside the seminiferous tubule lumen
275 and intertubular compartment (score 3);

- 276 2. Patients with vast areas of red blood cells bleeding in the intertubular
277 compartment (score 2);
- 278 3. Patients with small areas of red blood cell bleeding in the intertubular
279 compartment (score 1);
- 280 4. Patients without red blood cell bleeding (score 0).

281

282 **HISTOCHEMISTRY TECHNIQUES**

283 **Mast cell counts**

284 Toluidine-blue staining was used to determine the number of mast cells. We investigated
285 15 testicular fields (20x magnification), and the cells were quantified per patient.

286

287 **PAS staining**

288 A Schiffs kit (Sigma-Aldrich, USA) was used for PAS staining, as per the manufacturer's
289 protocol. In brief, the sections were pre-treated with periodic acid for 5 min at RT, slowly
290 rinsed in distilled water, and then stained with Schiffs solution for 10 min at RT in the
291 dark. The nuclei were stained with hematoxylin for 5 min at RT, followed by six dips in
292 1% hydrochloric alcohol. After dehydration with 70, 90, and 100% graded alcohol, the
293 sections were immersed twice in xylene for 10 min each. Then, the slides were mounted
294 with a coverslip and sealed with Entellan resin (Sigma-Aldrich, USA). Images were
295 captured using light Olympus microscopy (BX-60).

296

297 **Masson's Trichrome and Picrosirius red**

298 Tissue samples were stained with Masson's Trichrome and Picrosirius red to assess
299 fibrosis and collagen types I and III. Images of the two techniques were captured in a Spot
300 Insight Color digital camera adapted for Olympus BX-40, using the Spot software version

301 3.4.5. To determine the area of fibrosis and differentiate the types of collagens, images of
302 three random areas of each patient were obtained at 100x magnification. Images were
303 analyzed with Image J v. 1.53c software (National Institutes of Health, USA) using the
304 Color Deconvolution tool, getting the average of the three areas evaluated(14).

305

306 **IMMUNOSTAINING**

307 For immunostaining, deparaffinized sections (5 µm thick) were dehydrated and submitted
308 to heat-induced antigenic recovery (water bath) with buffered sodium citrate (pH 6.0) at
309 90°C for 40 min. Then, the sections were immersed in BSA 3% (in PBS) solution to block
310 non-specific antibody binding and incubated overnight at 4 °C with primary antibodies
311 (Supplemental Table 2). Reactions were visualized using biotin-conjugated secondary
312 antibodies (anti-goat: 1:100 dilution, Abcam, ab6740; anti-mouse: 1:200 dilution, Imuny,
313 IC1M02; anti-rabbit: 1:200 dilution, Abcam, ab6720) combined with Elite ABC Kit
314 (Vector Laboratories, USA). Signal detection was obtained via peroxidase substrate 3,39-
315 diaminobenzidine (DAB; Sigma Aldrich, USA) reaction and counterstaining with
316 Mayer's hematoxylin (Merck, USA).

317 To identify targets of SARS-CoV-2 in the testis intertubular compartment, double-
318 immunofluorescence anti-S with anti-CD-68 or anti-Chymase was performed. Reactions
319 were visualized using Alexa-488 (1:100 dilution), Alexa-546 (1:200 dilution), and Alexa-
320 633 (1:200 dilution), all from Thermo Fisher Scientific, USA, and conjugated secondary
321 antibody. For ACE2 evaluation, we used anti-ACE2 (Proteintech, USA) and Alexa-594
322 (1:100 dilution) from Jackson ImmunoResearch, USA. Images were acquired using the
323 Nikon Eclipse Ti fluorescence microscope.

324 To analyze immunopositive macrophages and T lymphocytes, CD68 and CD3 positive
325 cells were quantified by counting 10 testicular fields at 400x magnification. Only cells

326 with visible nuclei, brown cytoplasm, and morphology compatible with the evaluated
327 cells were counted(15). Microvessel density analysis was also performed in 10 fields at
328 400x magnification, and only CD31 immunopositive structures with or without lumen
329 were counted (vessels containing muscle walls were not counted).

330

331 **TRANSMISSION ELECTRON MICROSCOPY**

332 Testes fragments were fixed by immersion in 4% glutaraldehyde (EMS, USA). Smaller
333 pieces (1-2 mm thickness) were obtained and postfixed in reduced osmium (1% OsO₄
334 and 1.5% potassium ferrocyanide in distilled water) for 90 min, dehydrated in ethanol,
335 and embedded in Araldite epoxy resin. Ultrathin sections (60 nm thick) were obtained
336 using a diamond knife on a Leica EM UC6 ultramicrotome (Leica Microsystems) and
337 mounted on 200 mesh copper grids (Ted Pella). The ultrathin sections were stained with
338 lead citrate (Merck, USA) and analyzed using a transmission electron microscope (Tecna
339 G2-12 Thermo Fisher Scientific/FEI, USA).

340

341 **ENZYMATIC AND HORMONE MEASUREMENTS**

342 The enzymatic activity of Myeloperoxidase (MPO) and N-Acetyl-BD-glucosaminidase
343 (NAG) and the total concentration of testosterone and angiotensin II were determined in
344 human testis homogenates. For this purpose, 50 mg of snap-frozen testis from deceased
345 COVID-19 patients and Controls was homogenized in 450 µL cold PBS supplemented
346 with a protease inhibitor cocktail (Cat n° S8830, Sigma-Aldrich). After three freeze/thaw
347 cycles in a liquid nitrogen/water bath (37°C), the samples were centrifugated (14.000 g,
348 10 min, 4°C), and the supernatants were collected.

349 For MPO and NAG measurements, 100 µL of tissue homogenates were mixed 1:1 in
350 MPO buffer assay (0,1M Na₃PO₄, 0.1% [w/v] HETAB, pH 5.0) or NAG buffer assay

351 (0,2M citric acid, 0,2M Na₂HPO₄, pH 4.5), respectively, just prior the freeze/thaw step.
352 The activity of MPO and NAG, which is an indirect estimation of the abundance of
353 neutrophils and macrophages, was measured in a colorimetric enzymatic assay.
354 Intratesticular testosterone levels were determined in testis homogenates using a
355 chemiluminometric immunoassay run on the Atellica IM Analyzer (Siemens Healthcare
356 Diagnostics). The concentration of Angiotensin II was measured by ELISA, according to
357 the procedures supplied by the manufacturer (MyBioSource, San Diego, CA, USA). The
358 kit applied the sandwich ELISA technique. The sensitivity of the assay was 12 pg/mL.

359

360 **TESTICULAR GENE EXPRESSIONS**

361 Total RNA was isolated from testes using AurumTM Total RNA MiniKit[®] (BioRad,
362 USA). A Nanodrop spectrophotometer (Thermo Fischer, USA) was used to measure the
363 quantity and integrity of total RNA. RNA (2 µg/sample) was reverse transcribed using
364 the iScript cDNA Synthesis Kit (BioRad, USA). cDNAs (10 ng) were amplified by qPCR
365 with iTaq Universal SYBR Green Supermix (BioRad, USA) in Rotor-Gene Q (Qiagen,
366 USA). The primer sequences used can be found in Supplemental Table 2. Relative levels
367 of expression were determined by normalization to RPL19 e HPRT1 using the $\Delta\Delta CT$
368 method. The testicular gene expressions were displayed as Heat maps (Fig.5, Fig.5 and
369 Fig.6) and individual graphs (Supplemental Fig.6 and Supplemental Fig.7).

370

371 **STATISTICAL ANALYSES**

372 Demographics and clinical characteristics were presented using descriptive statistics:
373 mean and standard deviation (SD) for normally distributed continuous data; median and
374 interquartile range (IQR) for non-normally distributed continuous data; and proportions
375 and frequencies for categorical data. The presence and the strength of a linear relationship

376 between demographics and clinical characteristics and the damage to the testicles were
377 analyzed using Spearman correlation.

378 All quantitative data were tested for normality and homoscedasticity of the variances
379 following Kolmogorov–Smirnov (Dallal–Wilkinson–Lilliefor) and Bartlett tests. Data
380 from the fluorometry assay analyses were evaluated by one-way ANOVA for
381 comparisons within groups, followed by Newman-Keuls (normal distribution).
382 Histomorphometric and gene expression data were analyzed by unpaired Student's t-test,
383 comparing COVID-19 groups to Controls and COVID-19-P1 to COVID-19-P2 (COVID-
384 19-P3 was not considered for statistics). The data obtained were represented as the mean
385 \pm SEM and geometric mean \pm SD. Graphs and statistical analyses were conducted using
386 GraphPad PRISM v6.0 (GraphPad Software, Inc). Differences were considered
387 statistically significant at $p < 0.05$.

388

389 **RESULTS AND DISCUSSION**

390 **Hypertension, diabetes, and obesity are the main comorbidities**

391 All 11 patients studied herein were admitted to the ICU in in Belo Horizonte
392 (Brazil) hospitals due to severe pulmonary symptoms. Mean age was 63.9 ± 13.11 years
393 (range 46 to 8) and the mean body mass index was $32.18 \text{ Kg/m}^2 \pm 6.04$ (range 25.95 –
394 44.46). All patients had children, except for patient #9. Table 1 summarizes the patients'
395 clinical characteristics. None of the patients presented scrotal symptoms or complaints
396 during their hospital stay, nor their clinical history revealed previous testicular disorders.

397 The mean disease duration (from onset to death) was 23.73 ± 8.24 days (range 13–
398 38), while the meantime of ICU admission to death was 15.81 ± 6.19 days (range 8–25).
399 All patients presented fever during hospitalization, with six of them for longer than 24
400 hours. However, we did not evidence a strong correlation between fever and the

401 development of testicular pathogenesis (Spearman's $\rho = -0.195$; $p = 0.57$). Recent data
402 indicate that fever is not correlated with the sperm quality alteration after SARS-CoV-2
403 infection(16). The most prevalent comorbidities were systemic arterial hypertension (nine
404 cases), diabetes mellitus (six cases), and obesity (six cases).

405

406 **SARS-CoV-2 reliable detection in testes**

407 We first tested the testicular tissue using a conventional RT-qPCR protocol for
408 SARS-CoV-2 and only patient #8 was positively detected (cycle threshold - CT=38). To
409 improve detection and reduce interference of intrinsic tissue factors, we performed a
410 cDNA synthesis using SARS-CoV-2 specific viral primers. The RT-qPCR revealed the
411 virus presence in 10 of 11 patients (Table 2). Previous studies presented conflicting results
412 regarding the detection of SARS-CoV-2 RNA in the testes(2–5).

413 To confirm the genetic data, we used a nano-designed sensor (which employs
414 localized surface plasmon resonance - LSPR)(11) to detect the SARS-CoV-2 Spike (S)-
415 protein and the nucleocapsid (N)-protein (Supplemental Fig.1a-q). S-protein was found
416 in all, while N-protein was observed in nine patients (Table 2 and Supplemental Fig.1m-
417 q). Prominent S-protein immunolabeling was evidenced in testes of all COVID-19
418 patients (Supplemental Fig.2), especially in patient #8 (positively detected by all
419 methodologies). These findings suggest that the SARS-CoV-2 tropism for testes is higher
420 than previously thought and that conventional RT-qPCR protocol may only detect
421 infected testes with a higher viral load. Our data suggest that more sensitive techniques
422 are required for the reliable detection of SARS-CoV-2 (even in a low viral titer) in testes.

423

424 **Main infected cells in testis parenchyma**

425 Several infected monocytes/macrophages (CD68+) were detected surrounding
426 blood vessels and migrating to the parenchyma (IF and TEM data), suggesting that these
427 cells might be delivering SARS-CoV-2 to testis (Fig.1a-c, arrows), contributing to
428 infection of testicular cells. Infected macrophages were confirmed through double
429 immunofluorescence and TEM (Fig.1d-g). Monocytes/macrophages were also found
430 inside the tubular compartment, indicating a possible route for viral spreading inside the
431 seminiferous tubules (Fig.1h). Conversely, chymase positive mast cells were not labeled
432 for S-protein (Supplemental Fig.3a-b).

433 Most S-protein labeling was identified inside the seminiferous tubules, mainly in
434 germ cells (Fig.1 i-m). While we show germ cells positive for the S-protein, other authors
435 showed positivity for the N-protein(4). In some areas, spermatogonial cells displayed
436 intense S-protein labeling compared to spermatocytes and spermatids (Fig.1n, red
437 arrowhead). Nevertheless, SARS-CoV-2 S-protein was detected in spermatogonia,
438 spermatocytes and spermatids (Fig.1o-t). Patients who died up to 20 days after intensive
439 care unit (ICU) admission presented the highest mean fluorescence index in the testis
440 (Supplemental Fig.2a). Germ cells infected with SARS-CoV-2 increase the concerns of
441 potential sexual transmission, reinforced by the detection of SARS-CoV-2 RNA in semen
442 of patients who suffered the severe form of COVID-19(17).

443 Some Sertoli, Leydig (highly express ACE2(18)), and peritubular myoid cells also
444 presented viral particles in their cytoplasm (TEM data), albeit with lower S-protein
445 immunolabelling intensity (Fig. 2a-c', arrowheads and insets). However, many of these
446 cells did not show obvious viral particles in the cytoplasm (TEM data) (Fig. 2e-j).

447

448 **Viral replication and viability**

449 TEM analyses identified a viral replication factory in macrophages, which are
450 known to express ACE2 and TMPRSS2(19), and in spermatogonial cells, which highly
451 express TMPRSS2(18) (Fig.3a-f). In both cell types, we observed SARS-CoV-2
452 replication complexes with the formation of convoluted membranes (replication
453 membranous webs, RMW) containing double-membrane vesicles (DMV) and
454 Endoplasmic Reticulum Golgi Intermediate Complex (ERGIC) showing new virions
455 (Fig.3c-f). These morphological features are in accordance with SARS-CoV-2 replication
456 in the cell cytoplasm(20).

457 The testicular immune privilege prevents the autoimmune attack of haploid germ
458 cells, but it also allows viruses to escape immunosurveillance(21). The “macrophage
459 paradox”, described in SARS-CoV-2-induced lung damages(19) may also apply to the
460 testes. Thus, although macrophages combat viral infections, they can act as Trojan
461 horses(19), facilitating viral entrance and replication in testis. While it is possible that
462 the testis can be infected by direct invasion caused by viremia, our results point that
463 infected monocytes/macrophages migrating (e.g., from lungs) may also be actively
464 transporting the virus into the testes(22). Identifying viral access to the testis and the local
465 of replication are relevant because testicular immune tolerance may hamper the viral
466 clearance from the human body, like what is observed for other viruses(21).

467 In a BSL-3 lab, we exposed VERO CCL-81 cell cultures to testicular homogenates
468 from an infected patient and found that SARS-CoV-2 was infective and able to replicate
469 in these cells. This data was confirmed by immunohistochemistry, the cytopathic effect
470 in the infected VERO cell culture and conventional RT-qPCR (Fig.3g-j), indicating that
471 we were not observing just fragments of viral particles.

472 Previous research indicated that SARS-CoV-2 negativity in RT-qPCR tests (at
473 least in two consecutive assays) usually occurs between 6-12 days from the time of onset

474 of symptoms(23). However, according to our data, the virus remains viable for a longer
475 period within the testis. Indeed, SARS-CoV-2 was detected in the testis of patient #1,
476 who died 26 days after symptoms' onset (Fig.3k). Thus, our findings suggest that the
477 testes may serve as sanctuaries for SARS-CoV-2, maintaining infective viruses for
478 extended periods. Testis environment can even be related to the delayed viral clearance
479 in men compared to women(24). Furthermore, the testes may not be neglected in
480 evaluating the patients' clinical condition because it is a site of viral replication and
481 consequently a source of viral load.

482

483 **Clinical data and testicular alterations**

484 Since SARS-CoV and SARS-CoV-2 infection may impair male GC development,
485 leading to GC loss(2,25), we categorized the COVID-19 patients according to the
486 architecture and histology of seminiferous tubules to understand the evolution of the
487 testicular pathogeny, emphasizing the preservation of different generations of germ cells.
488 Critically ill patients who maintained elongated spermatids in the seminiferous epithelium
489 were categorized as the first phase (patients #6, #7, #8, #9, and #11). Patients presenting
490 primary spermatocytes as the most advanced germ cell type were categorized as the
491 second phase (patients #1, #3, #4, #5, and #10). Specifically, patient #2 was classified in
492 the third phase because his testis presented few spermatogonia inside the seminiferous
493 tubules (Fig.4a-c). A weak correlation (Spearman's = -0.33; p=0.30) was observed
494 between the germ cell loss and the patient's age. Furthermore, we did not observe a strong
495 correlation between patients' age and the progression of the pathogeny (Spearman's =
496 0.33; p= 0.31).

497 Remarkably, there was a positive correlation (Spearman's = 0.6862; p=0.0197)
498 between the above-described phases and the time from ICU admission to death (Fig.4d).

499 All patients of Phase I died less than 20 days after ICU admission, with most deceasing
500 well before 20 days. In the second phase, all patients died 20-23 days after ICU admission.
501 Patient #2 (third phase) died after 25 days. Our findings suggest that the more extended
502 severe condition (ICU stay), the lower the number of surviving germ cells. This data
503 raises concerns that patients that survive severe COVID-19 (with an extended stay in
504 ICU) have an increased risk of developing infertility.

505

506 **Imbalanced renin-angiotensin system**

507 The interaction of SARS-CoV-2 and ACE2 promotes this enzyme's
508 internalization, resulting in elevated levels of angiotensin II in the affected tissues(26).
509 We found ACE2 protein in spermatogonial, Leydig, and Sertoli cells of Controls and
510 COVID-19 patient testes (Fig.4f). However, testicular cells of COVID-19 patients
511 showed weak ACE2 staining intensity, specially inside the seminiferous tubules (Fig.4g-
512 i). qPCR revealed augmented ACE2 expression in the testis of first phase patients and
513 diminished in patients of the second and third phases (Fig.4j). ACE protein expression
514 reduced, whereas Angiotensin II Receptor Type 1 (AGT1R) increased in all phases
515 (Fig.4j).

516 COVID-19 patients presented more intensely immunolabeled testicular cells for
517 the AGT1R than Controls, particularly in Leydig cells, macrophages, and peritubular
518 myoid cells (Fig.4k-n). Angiotensin II levels were higher in the testis parenchyma of
519 COVID-19 patients than in Controls (Fig.4o). Although overstimulation of the ANG
520 II/AGT1R pathway underlies the damages observed in several tissues of COVID-19
521 patients(27), the present study is the first to show a role for this pathway in the testes.

522

523 **Mast cell and macrophage activation**

524 Total protein was significantly higher in testes from COVID-19 patients than
525 Controls (Supplemental Fig.3c), indicating chronic inflammation or infections(28). The
526 influx of immune cells can be mediated by angiotensin II, a potent pro-inflammatory
527 molecule(29), and factors secreted by activated macrophages(30) and mast cells(31). It
528 can also stimulate chemokines that promote mast cell infiltration(32) and regulate
529 migration and infiltration of monocytes/macrophages into tissues(33). Our morphological
530 and molecular data suggest that mast cells and macrophages play a critical role in
531 testicular pathogenesis.

532 The number of mast cells found in the testis of COVID-19 patients was ten times
533 higher than that found in Controls (Fig.5a-c). Immunohistochemistry revealed chymase-
534 positive mast cells, indicating that these cells are highly active(34) in the testes of the
535 COVID-19-affected patients (Fig.5d-g). Interestingly, mast cells were detected next to
536 areas of the testicular parenchyma displaying a high concentration of immune cells,
537 hemorrhagic areas, altered Leydig cells, interstitial fibrotic areas, damaged tunica propria,
538 and thickened tubular basal membrane (Supplemental Fig.3d-m). qPCR data showed that
539 Control testes present minimal expression of chymase (CMA1) and tryptase (TPSB2),
540 whereas all testicular samples from the COVID-19 patients showed increased expression
541 (Fig.5h). In first phase patients, mast cells were highly prevalent in the testes' intertubular
542 compartment. Second and third phase patients showed these cells inside the tubular and
543 intertubular compartments (Supplemental Fig.3d-m). Interestingly, increased number of
544 tryptase and chymase positive mast cells in testes is associated with testicular
545 inflammation and infertility in men(35).

546 Testes of COVID-19 patients also presented elevated mRNA levels of the pro-
547 inflammatory factors MCP1 (10x higher) and COX2 (Fig.5h), which are stimulated by

548 Angiotensin II(36,37). MCP1 is particularly unfavorable for testicular pathogenesis
549 because it can attract more infected monocytes (Supplemental Fig.3n-o).

550 Macrophages (CD68+) numbers were augmented, and these cells were highly
551 active (NAG assay and PAS staining(38)) in infected testis (Fig.5i-q). Activated
552 macrophages are associated with spermatogenesis impairment or chronic orchitis(39).
553 These cells can compromise the immune-privileged testicular environment, secreting pro-
554 inflammatory cytokines and interfering with testicular homeostasis(40). Therefore, our
555 findings suggest a decisive contribution of activated mast cells and macrophages to the
556 pathophysiology of COVID-19 in the human testes, which could eventually induce
557 harmful effects on the reproductive health in severely ill patients.

558 Lymphocytes (CD3+) were frequently observed in the testes of COVID-19
559 patients, suggesting a prolonged infection (Fig.5r-v). Neutrophils were also identified in
560 testes of COVID-19 patients (Fig.5x); however, their activity (MPO assay) was not
561 altered when compared to Controls (Fig.5w). These data suggest that macrophages are
562 more active than neutrophils in the testes of COVID-19 patients.

563

564 **Effects on the tubular compartment**

565 While the germ cell population and tubular diameter diminished in COVID-19
566 patients (Supplemental Fig.4a-b), the tunica propria enlarged, reflecting a higher number
567 of peritubular myoid cells and collagen fibers (Supplemental Fig.4c-j). Interestingly, the
568 tunica propria and the basal membrane (PAS+) thickened next to mast cells and
569 macrophages and sometimes presented a corkscrew appearance (Supplemental Fig.4k-n)

570 There were many caspase-3 positive germ cells in the testes of all COVID-19
571 patients (Fig.6a-d). The rete testis area presented degenerating germ cells (Supplemental
572 Fig.4o), and BAD and BAX levels were augmented in nearly all COVID-19 patients

573 (Fig.6e). DAZL and TMPRSS2 genes, known to be highly expressed in germ cells,
574 diminished as the phases progressed (Fig.6e).

575 Tight junctions of the seminiferous tubules were also compromised in COVID-19
576 patients, with reduced levels of occludin and claudin-11 (Fig.6e). Expressions of critical
577 Sertoli cell genes (Sox9 and Gata4) were also reduced (Fig.6e). Moreover, the
578 seminiferous epithelium detached from the thickened tunica propria (Fig.6f and
579 Supplemental Fig.4p-t), indicating downregulation of tubular junctional proteins. These
580 tubular phenotypes can be stimulated by high levels of angiotensin II(41), activated mast
581 cells(42), and activated macrophages(43). Interestingly, proteases and cytokines released
582 by activated mast cells and macrophages can disrupt tight epithelial junctions and
583 deregulate the human blood-testis barrier(44).

584

585 **Leydig cells apoptosis and inhibition**

586 There was a gradual volumetric reduction of Leydig cells (Fig. 6g) as the testicular
587 pathogeny developed, in accordance with Yang et a. (2020)(45). Intratesticular
588 testosterone levels measured in the testicular homogenates of COVID-19 patients were
589 lower (~30 times) than the Controls (Fig. 6h). Caspase-3 immunolabelling revealed that
590 these cells were undergoing apoptosis (Fig.6i-l). Additionally, their morphology was
591 altered, presenting a vacuolated cytoplasm (with a degenerating content) (Fig.6m-n and
592 Supplemental Fig.5a-d).

593 Reduction in the expression of LHR, STAR, 3BHSD, and 17BHSD in the testis
594 of COVID-19 patients was consistent with the low number of Leydig cells (Fig.6e). The
595 levels of histamine H4 receptor (HRH4), an inhibitor of human steroidogenesis(46), were
596 highly augmented in the affected patients (Fig.5h). This data indicates that local histamine
597 can inhibit steroidogenesis in the testes of COVID-19 patients.

598 Mast cells producing histamines, high levels of angiotensin II, and pro-
599 inflammatory cytokines produced by macrophages can inhibit steroidogenesis(47).
600 Moreover, low levels of intratesticular testosterone disturb the immune-privileged
601 milieu(48) and compromise spermatogenesis(49).

602

603 **Testis fibrosis and vascular alterations**

604 Testicular fibrosis was commonly observed in the testis parenchyma of COVID-
605 19 patients. Collagen fibers increased progressively (Fig.6o-u), showing high amounts of
606 type I and III collagen in testis parenchyma (Fig.6t-u, Supplemental Fig.5e-h). Further,
607 the expression levels of Col3a were highly augmented in the testes of phase I patients
608 (Fig.6e). It is known that Angiotensin II, activated mast cells, and activated macrophages
609 stimulate collagen synthesis by fibroblasts(50–52).

610 Expressions of the angiogenic factors VEGF and PDGFA and small vessel
611 volumetric proportion (CD31+) increased in the testis of COVID-19 patients (Fig.6e).
612 Immature blood vessels (TEM and Immunohistochemistry data; CD31+ cells) were
613 observed inside the tunica propria, suggesting an angiogenic process (Fig,6v and
614 Supplemental Fig.5i-m). Red blood cells outside the testicular vasculature were
615 frequently observed in the testes of COVID-19 patients (Fig, 6w- α , arrows). First phase
616 patients presented many red blood cells inside the seminiferous tubule lumen and
617 intratesticular rete testis, possibly due to a reduction in tight epithelial junctions
618 (Supplemental Fig.5n). Some thrombi were detected inside the vascular system
619 (Supplemental Fig.5o).

620 Furthermore, Endothelin 1/2/3, a protein involved in blood-vessel
621 vasoconstriction, was highly expressed in the first phase patients but reduced in others

622 (Supplemental Fig.5q-t). The triad, angiotensin II, activated mast cells, and activated
623 macrophages can increase vascular permeability(31,53,54).

624 Concerning the study limitation, we should highlight important points of the
625 current study. Notably, the chronology of testicular pathogeny was based on the presence
626 of advanced germ cells in testis parenchyma and the time of ICU admission. Although
627 our histological and molecular alterations reinforced this conceptual classification, the
628 data of all individuals were also presented in a single group. Moreover, only severely ill
629 patients, who died from COVID-19, were included in the study. We should mention that
630 recent data on semen demonstrate that patients recovered from COVID-19 reestablish
631 their sperm quality after three months of the infection(54). Not all COVID-19 patients
632 studied presented the same comorbidities, and Controls were not submitted to the
633 medications used for COVID-19 patients. On the other hand, we managed to harvest and
634 process the testicles on the same day as the death occurred, in contrast with many cadaver
635 studies with long organ collection delays, which may have compromised the precise
636 histology, detection of virion particles, and perception of peptides, mRNA and hormones
637 fluctuations.

638

639 **CONCLUSIONS**

640 Herein, we used different and sensitive methods to detect SARS-CoV-2 proteins,
641 RNA, and virus particles in the testis. In figure 7, we hypothesized the potential viral,
642 cellular, and molecular mechanisms of infection and damage by SARS-CoV-2 in testes
643 of non-vaccinated and severely ill patients. A direct influence of SARS-CoV-2 in
644 testicular cells might deregulate ACE2, elevating the levels of angiotensin II, a potent
645 pro-inflammatory and angiogenic peptide. Angiogenic and inflammatory factors might
646 induce the infiltration and activation of mast cells and macrophages. Therefore, the

647 deleterious effects evidenced in the testes of COVID-19 patients, i. e. fibrosis, vascular
648 alteration, inflammation, tunica propria thickening, Sertoli cell barrier loss, germ cell
649 apoptosis, and inhibition of Leydig cells, may be associated with elevated angiotensin II
650 and activation responses of mast cells and macrophages (Fig. 7a). A protein-protein (or
651 gene-gene) network constructed from the STRING database (Fig. 7b) shows the
652 interaction of genes associated with angiotensin II regulation, activation of mast cells and
653 macrophages, and testis tubular and intertubular compartment alterations.

654 Our multidisciplinary findings might contribute to a better understanding of
655 SARS-CoV-2 tropism, biology, and impact on testes and male fertility. This is the first
656 study that shows: 1) the high SARS-CoV-2 tropism to the testis; 2) one mode of SARS-
657 CoV-2 entrance in testes; 3) SARS-CoV-2 preferred infection and replication in
658 spermatogonia and macrophages; 4) that the virus remains infective after a long infection
659 period in the testes (viral reservoir); 5) high levels of angiotensin II and activated mast
660 cells and macrophages are critical players in promoting all testicular alterations; 6) the
661 more extended severe condition, the lower the number of surviving germ cells; 7)
662 fluctuation in several essential testicular genes; 8) that the intratesticular testosterone
663 levels are 30 times reduced in testes of COVID-19 patients; 9) the prevalent types of
664 collagen present in SARS-CoV-2 mediated testicular fibrosis; 10) the fluctuation of
665 vasoconstrictive peptides in testes of COVID-19 critically ill patients.

666

667 **ACKNOWLEDGEMENTS**

668 This work was primarily financed by Ferring COVID-19 Investigational Grant (grant n°
669 FIN0042393, to G.M.J.C). G.M.J.C. also received resources from FAPEMIG (APQ-
670 01078-21). Other specific grants from coauthors punctually helped in some experiments
671 and logistics of the present study. AFV was supported by a FAPESP (grant #18/17647-
672 0) when the study was conducted. GRFC is supported by a FAPESP (grant #20/07419-

673 0). M.H.F. was supported by the Laboratório São Paulo/BH-MG. M.L.N. is supported by
674 FAPESP (grant # 2019/07250-9 and #2020/04836-0) and CNPq. F.G.F. received grants
675 from FAPEMIG (CBB-APQ-03081-17, and CBB- APQ-04295-17), and from Rede
676 Mineira de Pesquisa e Inovação para Bioengenharia de Nanossistemas (RM PI-BEM –
677 FAPEMIG - TEC - RED-00282-16). R.S.A was supported by CNPq (R.S.A.:
678 312688/2017-2 and 439119/2018-9). We thank Dr. Luiz Orlando Ladeira, Dr. Rodrigo
679 Ribeiro Resende, Dr. Ary Correa Jr, and Dr. Iara Borges for their help and gently allowing
680 the use of their Lab equipment. We also thank the Image Acquisition and Processing
681 Center (CAPI-ICB/UFMG) and the Centro de Microscopia da UFMG (CM-UFMG) for
682 their technical assistance. We especially thank the families of the deceased COVID-19
683 patients for understanding the importance of our study.

684

685 **AUTHOR CONTRIBUTIONS**

686 Study design: G.M.J.C., G.D.C., A.K.Z., L.G.G.P., M.H.F. Performed experiments:
687 G.M.J.C., S.M.S.N.L, A.F.A.F., N.T.W., M.R.B., G.H.C.S., A.F.V., L.M.A., F.R.S.,
688 A.L.C.B., G.R.F.C; E.M.N.M, R.S.A., L.M.K., G.R.F.C, E.M.N.M., L.A.M., C.B., P.R,
689 Y.L.G. Data analysis: G.M.J.C., S.M.S.N.L, M.R.B., A.F.A.F., N.T.W., G.H.C.S., A.F.V,
690 L.M.A., G.D.C., H.C.G., V.V.C., F.G.F., M.L.N., M.B.E., A.M.M., K.W.O., B.P.M.,
691 M.S.P., T.P.F., M.H.F. Intellectual, technical and resource support: G.M.J.C., G.D.C.,
692 H.C.G., V.V.C., F.G.F., M.L.N., R.S.A, G.B.M., A.K.Z, M.H.F. Wrote the first draft of
693 the paper: G.M.J.C., A.K.Z., M.H.F. All authors reviewed and approved the final version
694 of the manuscript.

695 **COMPETING INTEREST DECLARATION**

696 The authors have no conflicts of interest to declare

697 **ADDITIONAL INFORMATION**

698 Correspondence and requests for materials should be addressed to Guilherme M. J. Costa,
699 e-mail: gmjc@ufmg.br.

700

701 REFERENCES

- 702 1. Chakravarty D, Nair SS, Hammouda N, Ratnani P, Gharib Y, Wagaskar V, et al.
703 Sex differences in SARS-CoV-2 infection rates and the potential link to prostate
704 cancer. *Commun Biol* [Internet] 2020;3(1):1–12. Available from:
705 <http://dx.doi.org/10.1038/s42003-020-1088-9>
- 706 2. Ma X, Guan C, Chen R, Wang Y, Feng S, Wang R, et al. Pathological and
707 molecular examinations of postmortem testis biopsies reveal SARS-CoV-2
708 infection in the testis and spermatogenesis damage in COVID-19 patients. *Cell*
709 *Mol Immunol* [Internet] 2021;18(2):487–9. Available from:
710 <http://dx.doi.org/10.1038/s41423-020-00604-5>
- 711 3. Hu B. Absence of 2019 novel coronavirus in semen and testes of COVID-19
712 patients. 2020;1–41.
- 713 4. Duarte-Neto AN, Teixeira TA, Caldini EG, Kanamura CT, Gomes-Gouvêa MS,
714 dos Santos ABG, et al. Testicular pathology in fatal COVID-19: A descriptive
715 autopsy study. *Andrology* 2021;(June):1–11.
- 716 5. Achua JK, Chu KY, Ibrahim E, Khodamoradi K, Delma KS, Iakymenko OA, et
717 al. Histopathology and ultrastructural findings of fatal COVID-19 infections on
718 testis. *World J Mens Health* 2020;39(1):65–74.
- 719 6. Edenfield RC, Easley CA. Implications of testicular ACE2 and the renin–
720 angiotensin system for SARS-CoV-2 on testis function. *Nat Rev Urol* 2021;
- 721 7. Lu X, Wang L, Sakthivel SK, Whitaker B, Murray J, Kamili S, et al. US CDC
722 real-time reverse transcription PCR panel for detection of severe acute respiratory
723 syndrome Coronavirus 2. *Emerg Infect Dis* 2020;26(8):1654–65.
- 724 8. Nikoobakht B, El-Sayed MA. Preparation and growth mechanism of gold
725 nanorods (NRs) using seed-mediated growth method. *Chem Mater*
726 2003;15(10):1957–62.
- 727 9. Andrade LM, Martins EMN, Versiani AF, Reis DS, da Fonseca FG, Souza IP d.,
728 et al. The physicochemical and biological characterization of a 24-month-stored
729 nanocomplex based on gold nanoparticles conjugated with cetuximab
730 demonstrated long-term stability, EGFR affinity and cancer cell death due to
731 apoptosis. *Mater Sci Eng C* [Internet] 2020;107(September 2019):110203.
732 Available from: <https://doi.org/10.1016/j.msec.2019.110203>
- 733 10. Reis DS, de Oliveira VL, Silva ML, Paniago RM, Ladeira LO, Andrade LM.
734 Gold nanoparticles enhance fluorescence signals by flow cytometry at low
735 antibody concentrations. *J Mater Chem B* 2021;9(5):1414–23.
- 736 11. Versiani AF, Martins EMN, Andrade LM, Cox L, Pereira GC, Barbosa-Stancioli
737 EF, et al. Nanosensors based on LSPR are able to serologically differentiate


- 738 dengue from Zika infections. *Sci Rep* [Internet] 2020;10(1):1–17. Available
739 from: <https://doi.org/10.1038/s41598-020-68357-9>
- 740 12. Crunfli F, Carregari VC, Veras FP, Vendramini PH, Valença GF, Saraiva A, et
741 al. SARS-CoV-2 infects brain astrocytes of COVID-19 patients and impairs
742 neuronal viability. *medRxiv* 2021;
- 743 13. Caldeira-Brant AL, Martinelli LM, Marques MM, Reis AB, Martello R, Almeida
744 FRCL, et al. A subpopulation of human Adark spermatogonia behaves as the
745 reserve stem cell. *Reproduction* 2020;159:437–51.
- 746 14. de Souza TA, de Campos CB, De Biasi Bassani Gonçalves A, Nunes FC,
747 Monteiro LN, de Oliveira Vasconcelos R, et al. Relationship between the
748 inflammatory tumor microenvironment and different histologic types of canine
749 mammary tumors. *Res Vet Sci* [Internet] 2018;119(October 2017):209–14.
750 Available from: <https://doi.org/10.1016/j.rvsc.2018.06.012>
- 751 15. Mahran AM, Elgamal DA, Ghafeer HH, Abdel-Maksoud SA, Farrag AA.
752 Histological alterations in Leydig cells and macrophages in azoospermic men.
753 *Andrologia* 2017;49(8).
- 754 16. Donders GGG, Bosmans E, Reumers J, Donders F, Jonckheere J, Salembier G, et
755 al. Sperm quality and absence of SARS-CoV-2 RNA in semen after COVID-19
756 infection: a prospective, observational study and validation of the SpermCOVID
757 test. *Fertil Steril* [Internet] 2021; Available from:
758 <https://doi.org/10.1016/j.fertnstert.2021.10.022>
- 759 17. Li D, Jin M, Bao P, Zhao W, Zhang S. Clinical Characteristics and Results of
760 Semen Tests Among Men With Coronavirus Disease 2019. *JAMA Netw open*
761 2020;3(5):e208292.
- 762 18. Wang Z, Xu X. scRNA-seq profiling of human testes reveals the. *Cells*
763 2020;9:920.
- 764 19. Abassi Z, Knaney Y, Karram T, Heyman SN. The Lung Macrophage in SARS-
765 CoV-2 Infection: A Friend or a Foe? *Front Immunol* 2020;11(June):1–5.
- 766 20. Hopfer H, Herzig MC, Gosert R, Menter T, Hench J, Tzankov A, et al. Hunting
767 coronavirus by transmission electron microscopy – a guide to SARS-CoV-2-
768 associated ultrastructural pathology in COVID-19 tissues. *Histopathology*
769 2021;78(3):358–70.
- 770 21. Liu W, Han R, Wu H, Han D. Viral threat to male fertility. *Andrologia*
771 2018;50(11):1–9.
- 772 22. Kosyreva A, Dzhililova D, Lokhonina A, Vishnyakova P, Fatkhudinov T. The
773 Role of Macrophages in the Pathogenesis of SARS-CoV-2-Associated Acute
774 Respiratory Distress Syndrome. *Front Immunol* 2021;12(May):1–16.
- 775 23. Chang D, Mo G, Yuan X, Tao Y, Peng X, Wang FS, et al. Time kinetics of viral
776 clearance and resolution of symptoms in novel Coronavirus infection. *Am J*
777 *Respir Crit Care Med* 2020;201(9):1150–2.
- 778 24. Fernández O, Kang S, Laily Noor Ikhsanto jurusan teknik mesin, Aceh kue
779 tradisional khas. Delayed clearance of SARS-CoV2 in male compared to female
780 patients: High ACE2 expression in testes suggests possible existence of gender-

- 781 specific viral reservoirs. 2020;2017(1):1–9.
- 782 25. Xu J, Qi L, Chi X, Yang J, Wei X, Gong E, et al. Orchitis: A complication of
783 severe acute respiratory syndrome (SARS). *Biol Reprod* 2006;74(2):410–6.
- 784 26. Davidson AM, Wysocki J, Batlle D. Interaction of SARS-CoV-2 and other
785 coronavirus with ACE (angiotensin-converting enzyme)-2 as their main receptor:
786 Therapeutic implications. *Hypertension* 2020;1339–49.
- 787 27. Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting
788 enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection.
789 *Eur J Clin Microbiol Infect Dis* 2021;40(5):905–19.
- 790 28. Bydlinski N. Mapping the testicular interstitial fluid proteome from normal rats.
791 2013.
- 792 29. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and
793 inflammation: The effect of angiotensin-converting enzyme inhibition and
794 angiotensin II receptor blockade. *J Hum Hypertens* 2007;21(1):20–7.
- 795 30. Fujiwara N, Kobayashi K. Macrophages in inflammation. *Curr Drug Targets
796 Inflamm Allergy* 2005;4(3):281–6.
- 797 31. Krystel-Whittemore M, Dileepan KN, Wood JG. Mast cell: A multi-functional
798 master cell. *Front Immunol* 2016;6(JAN):1–12.
- 799 32. Jones SE, Kelly DJ, Cox AJ, Zhang Y, Gow RM, Gilbert RE. Mast cell
800 infiltration and chemokine expression in progressive renal disease. *Kidney Int*
801 2003;64(3):906–13.
- 802 33. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant
803 protein-1 (MCP-1): An overview. *J Interf Cytokine Res* 2009;29(6):313–25.
- 804 34. Chen SJ, Duan YG, Haidl G, Allam JP. Predominance of IL-17-producing
805 tryptase-positive/chymase-positive mast cells in azoospermic chronic testicular
806 inflammation. *Andrologia* 2016;48(6):617–25.
- 807 35. Maciel TT, Moura IC, Hermine O. The role of mast cells in male infertility.
808 *F1000Prime Rep* 2015;7:627–34.
- 809 36. Morinelli TA, Walker LP, Ullian ME. COX-2 expression stimulated by
810 Angiotensin II depends upon AT1 receptor internalization in vascular smooth
811 muscle cells. *Biochim Biophys Acta - Mol Cell Res* 2008;1783(6):1048–54.
- 812 37. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin
813 II induces monocyte chemoattractant protein-1 gene expression in rat vascular
814 smooth muscle cells. *Circ Res* 1998;83(9):952–9.
- 815 38. Fenollar F, Raoult D. Whipple’s Disease. *Clin Diagnostic Laboratoty Immunol*
816 2001;8(1):1–8.
- 817 39. Goluža T, Boscanin A, Cvetko J, Kozina V, Kosović M, Bernat MM, et al.
818 Macrophages and leydig cells in testicular biopsies of azoospermic men. *Biomed
819 Res Int* 2014;2014.
- 820 40. Frungieri MB, Calandra RS, Lustig L, Meineke V, Köhn FM, Vogt HJ, et al.
821 Number, distribution pattern, and identification of macrophages in the testes of

- 822 infertile men. *Fertil Steril* 2002;78(2):298–306.
- 823 41. Welter H, Huber A, Lauf S, Einwang D, Mayer C, Schwarzer JU, et al.
824 Angiotensin II regulates testicular peritubular cell function via AT1 receptor: A
825 specific situation in male infertility. *Mol Cell Endocrinol* [Internet] 2014;393(1–
826 2):171–8. Available from: <http://dx.doi.org/10.1016/j.mce.2014.06.011>
- 827 42. Meineke V, Frungieri MB, Jessberger B, Vogt HJ, Mayerhofer A. Human
828 testicular mast cells contain tryptase: Increased mast cell number and altered
829 distribution in the testes of infertile men. *Fertil Steril* 2000;74(2):239–44.
- 830 43. Fijak M, Pilatz A, Hedger MP, Nicolas N, Bhushan S, Michel V, et al. Infectious,
831 inflammatory and “autoimmune” male factor infertility: How do rodent models
832 inform clinical practice? *Hum Reprod Update* 2018;24(4):416–41.
- 833 44. Loveland KL, Klein B, Poeschl D, Indumathy S, Bergmann M, Loveland BE, et
834 al. Cytokines in male fertility and reproductive pathologies: Immunoregulation
835 and beyond. *Front Endocrinol (Lausanne)* 2017;8(NOV):1–16.
- 836 45. Yang M, Chen S, Huang B, Zhong JM, Su H, Chen YJ, et al. Pathological
837 Findings in the Testes of COVID-19 Patients: Clinical Implications. *Eur Urol*
838 *Focus* [Internet] 2020;6(5):1124–9. Available from:
839 <https://doi.org/10.1016/j.euf.2020.05.009>
- 840 46. Abiuso AMB, Varela ML, Haro Durand L, Besio Moreno M, Marcos A, Ponzio
841 R, et al. Histamine H4 receptor as a novel therapeutic target for the treatment of
842 Leydig-cell tumours in prepubertal boys. *Eur J Cancer* 2018;91:125–35.
- 843 47. Hales DB. Testicular macrophage modulation of Leydig cell steroidogenesis. *J*
844 *Reprod Immunol* 2002;57(1–2):3–18.
- 845 48. Zhao S, Zhu W, Xue S, Han D. Testicular defense systems: Immune privilege
846 and innate immunity. *Cell Mol Immunol* 2014;11(5):428–37.
- 847 49. Rey RA, Grinspon RP, Gottlieb S, Pasqualini T, Knoblovits P, Aszpis S, et al.
848 Male hypogonadism: an extended classification based on a developmental,
849 endocrine physiology-based approach. *Andrology* 2013;1(1):3–16.
- 850 50. Che ZQ, Gao PJ, Shen WL, Fan CL, Liu JJ, Zhu DL. Angiotensin II-stimulated
851 collagen synthesis in aortic adventitial fibroblasts is mediated by connective
852 tissue growth factor. *Hypertens Res* 2008;31(6):1233–40.
- 853 51. Cairns JA, Walls AF. Mast cell tryptase stimulates the synthesis of type I
854 collagen in human lung fibroblasts. *J Clin Invest* 1997;99(6):1313–21.
- 855 52. Minutti CM, Knipper JA, Allen JE, Zaiss DMW. Tissue-specific contribution of
856 macrophages to wound healing. *Semin Cell Dev Biol* [Internet] 2017;61:3–11.
857 Available from: <http://dx.doi.org/10.1016/j.semcdb.2016.08.006>
- 858 53. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation.
859 *Med Sci Monit* 2005;11(6):194–205.
- 860 54. Guo L, Akahori H, Harari E, Smith SL, Polavarapu R, Karmali V, et al. CD163+
861 macrophages promote angiogenesis and vascular permeability accompanied by
862 inflammation in atherosclerosis. *J Clin Invest* 2018;128(3):1106–24.
- 863

864 FIGURES

865 Figure 1



866


867

868


869 **Fig. 1 SARS-CoV-2 infection in monocytes, macrophages and germ cells.** a) immunofluorescence for S-protein in testicular parenchyma showing positive germ cells
870 (red arrowhead), monocytes (white arrow), macrophages (orange arrowhead) and Leydig
871 cells (green arrowhead); a') negative control omitting the primary antibody (Scale bars =
872 a: 50 μ m; a': 40 μ m). b-c) TEM images showing infected infiltrative monocytes (Mono,
873 arrows); Yellow = disrupted cytoplasm of endothelial cells; Red boxes = cytoplasmic
874 areas replenished with viral particles; Inserts = high magnification of viral particles (Scale
875 bars = g: 2 μ m; h: 200nm). d-f) 3D reconstruction of a double immunofluorescence for
876 CD68 (w, red color) and S-protein (x, green color), depicting an infected macrophage (y,
877 merge – yellow color) (Scale bars = 10 μ m). g) TEM image of an infected macrophage
878 (m) showing a viral particle in its cytoplasm (insert). h) Presence of macrophages (arrows)
879 inside the seminiferous tubule (green arrow) and in the interstitial area (red arrow) (Scale
880 bar = 10 μ m). i-l) different types of infected germ cells: i: Spermatogonial cell (Spg); j:
881 Pachytene spermatocytes (P); k: Round spermatids (R); l: Elongated spermatids (E)
882 (Scale bars = 15 μ m). m-n) immunofluorescence against the S-protein showing that
883 spermatogonial cells (red arrowheads) are more intensely labeled than other germ cells.
884 (Scale bars = a: 30 μ m; b: 10 μ m). o-t) TEM images showing viral particles (in low and
885 high magnification) in germ cells, as follows: o-p) Spermatogonial cell (Spg) (Scale bars
886 = a: 1 μ m; b: 200nm); q-r) Pachytene spermatocytes (P, arrow) (Scale bars = c: 5 μ m; d:
887 200nm); s-t) Round spermatids (R) (Scale bars = e: 2 μ m; f: 200nm). Immunofluorescence
888 images in the testis of patient #8. TEM images in testes from patients #1, #7 and #8. Blue
889 = dapi counterstaining; green staining = IgG-CFL 488; red staining = IgG- 546. ST =
890 seminiferous tubule cross-section; IC = intertubular compartment; BV = blood vessel.
891
892
893

894 **Figure 2**

Infected cells



Non-infected cells



896

897 **Fig. 2 SARS-CoV-2 infection in Sertoli, Leydig and peritubular myoid cells. a)**

898 Immunofluorescence against S-protein evidencing weak labeling in peritubular myoid

899 (pink arrowhead) and Leydig cells (green arrowhead) (Scale bar =15 μ m). b-d') TEM

900 images showing viral particles (in low and high magnification) in Sertoli cell (SC) (Scale

901 bars = b: 2 μ m; b': 500nm); Leydig cell (LC) (Scale bars = c: 500nm; c': 200nm and

902 peritubular myoid cell (My) (Scale bars = d: 200nm; d': 100nm). e-g) TEM images of

903 non-infected Sertoli cells (SC, pink) (Scale bars = e: 2 μ m f-g: 5 μ). h) 3D reconstruction

904 of a seminiferous tubule cross-section showing non-labeled areas surrounding germ cells

905 (red arrowheads) (Scale bar = 40 μ m). i-j) high magnification of non-infected Leydig cells.

906 Arrow = tubular crest of a mitochondria (mi) (Scale bars = 500nm). Immunofluorescence

907 images in the testis of patient #8. TEM images in testes from patients #1, #7 and #8.

908

909

910

911

912

913


914

915

916

917

918 **Figure 3**



919

920

921

922

923

924

925

926 **Fig. 3. Infective SARS-CoV-2 particles formation and replication activity in Vero**
927 **cells.** a-f) TEM images of testicular parenchyma (Scale bars = a: 5µm; b: 500nm; c:
928 200nm; d: 200nm; e: 200nm; f:100nm). a) altered seminiferous tubule cross-section,
929 depicting a macrophage in tunica propria containing a Replication Membranous Web
930 (RMW; blue box) and a spermatogonial cell displaying an Endoplasmic Reticulum Golgi
931 Intermediate Complex (ERGIC, white box). The pink box indicates a spermatogonial cell
932 clone surrounded by the cytoplasm of a Sertoli cell (labeled in pink). b-c) higher
933 magnifications of spermatogonial cells showing new virions (labeled in green) inside the
934 ERGIC. d) higher magnification of the RMW from the macrophage depicted in “figure
935 a”, evidencing the presence of double-membrane vesicles (DMV). e-f) images from an
936 interstitial macrophage presenting RMW, DMV, and ERGIC filled with new virions
937 (labeled in green). g-i) infectivity of SARS-CoV-2 was evaluated in VERO CCL-81 cells
938 (Scale bars = 30µm). g) cell confluence of VERO CCL-81 cultures prior exposition to
939 testicular macerate. h) S-protein immunostaining showing infected VERO CCL-81 (blue
940 labeling: KPL TrueBlue Peroxidase Substrate). h’) negative control omitting the primary
941 antibody. i) cytopathic effect in VERO CCL-81 cell culture (empty area, *) after being
942 exposed to testicular homogenate for 72 hours. j) viral load in the VERO CCL-81 cell
943 culture supernatant was measured using RT-qPCR. Mock = control group; ND = non-
944 detected. k) schematic drawing indicating that SARS-CoV-2 remains active and
945 replicating in gonads 26 days after the onset of clinical symptoms.


946

947

948

949

950 **Figure 4**



951

952

953

954

955 **Fig 4. Imbalanced renin-angiotensin system in the testis of COVID-19 critically ill**
956 **patients.** a-d) initial categorization of COVID-19 patients according to the most advanced
957 germ cell in the seminiferous epithelium: phase 1 (P1), phase 2 (P2), and phase 3 (P3).
958 Toluidine-blue counterstaining (Scale bars = 50 μ m). a) Control patients showing
959 elongated spermatids (E). b) COVID-19 patients showing elongated spermatids (E),
960 spermatocytes (Spc) and spermatogonial cells (Spg). c) COVID-19 patients displaying
961 spermatocytes (Spc) and spermatogonial cells (Spg). d) COVID-19 patients presenting
962 spermatogonial cells (Spg) only. e) positive correlation between patient's phases and the
963 time frame from ICU admission to death (Spearman's rho = 0.6862; p=0.0197). f-i)
964 immunostaining of ACE2 in the testis of Control (f) and COVID-19 patients (g-i) (Scale
965 bars = 50 μ m). h') Negative control, omitting the primary antibody. Red: Alexa-594;
966 Blue: dapi; Green arrowheads: Leydig cell; red arrowheads: spermatogonial cell; blue
967 arrowheads: Sertoli cell. j) heat map of the evaluated genes related to the renin-
968 angiotensin system. The colors compare COVID-19 patients to Controls. Green: lower
969 expression than Controls. Red: Higher expression than Controls. k-n) immunostaining of
970 AGT1R in the testis of Control (k) and COVID-19 patients (l-n). Purple arrowheads:
971 peritubular myoid cells; green arrowheads: Leydig cells; orange arrowhead: macrophages
972 (Scale bars = 50 μ m). o) ELISA assay for angiotensin II (t-test; two tailed; infected groups
973 vs control; *p<0.05). P1, P2, P3: phase 1, 2, and 3 of the COVID-19 patients, respectively.
974 ST = seminiferous tubule; IC= intertubular compartment.


975

976

977

978

979 **Figure 5**



980


981

982

983 **Fig 5. Presence of activated mast cells and macrophages in the testis parenchyma of**
984 **COVID-19 critically ill patients.** a) toluidine blue staining showing an elevated number
985 of mast cells (arrows) in testis parenchyma (Scale bar = 50 μm). b) In some regions, mast
986 cells were identified inside the seminiferous tubules (red arrow). c) Number of mast cells
987 counted in 15 fields of testis parenchyma at 400x magnification (t-test; two tailed;
988 infected groups vs control; * $p < 0.05$). d-g) immunostaining for chymase in testes of
989 Control and COVID-19 patients. Activated mast cells (arrows) were observed in COVID-
990 19 patients only (Scale bars = 50 μm). d') Negative control (Scale bars = 50 μm). h) heat
991 map of the evaluated genes related to the mast cells and macrophages. The colors compare
992 COVID-19 patients to Controls. Green: lower expression than Controls. Red: Higher
993 expression than Controls. i-l) immunostaining for CD68 in testes of Control and COVID-
994 19 patients, illustrating the high prevalence of this cell in the deceased patients (Scale
995 bars = 50 μm). i') Negative control (Scale bars = 50 μm). m-o) PAS-positive monocytes
996 (red arrow) and macrophage (green arrow) indicating their activation (Scale bars = 15
997 μm). o') PAS-negative cells in the interstitial cells of a Control patient (Scale bar = 10
998 μm). p) Number of macrophages counted in 10 fields of testis parenchyma at 400x
999 magnification (t-test; two tailed; infected groups vs control; * $p < 0.05$). q) N-
1000 acetylglucosaminidase (NAG) assay indicating the activation of macrophages in COVID-
1001 19 patients' testes (t-test; two tailed; control vs infected group; $p > 0.05$). r-v)
1002 immunostaining for CD3 and lymphocyte number in testes of Control and COVID-19
1003 patients (t-test; two tailed; infected groups vs control; * $p < 0.05$) (Scale bars = 50 μm). r')
1004 Negative control (Scale bars = 50 μm). x-w) neutrophils and their activity (s: MPO assay)
1005 in testis parenchyma (t-test; two tailed; control vs infected group; $p > 0.05$) (Scale bar = 10
1006 μm).

1007

1008 **Figure 6**



1009



1010

1011

1012 **Fig. 6 Main testicular dysfunctions following SARS-CoV-2 infection.** a-d)
1013 immunostaining showing Caspase-3 positive germ cells (green arrows) in testes of
1014 Controls and COVID-19 patients (Scale bars = 50 μ m). a') Negative control (Scale bars
1015 = 50 μ m). e) heat map of critical genes from the tubular and intertubular compartments.
1016 The colors compare COVID-19 patients to Controls. Green: lower expression than
1017 Controls. Red: Higher expression than Controls. f) measurement of the tunica propria
1018 thickness. (t-test; two tailed; infected groups vs control; * p <0.05). g) Leydig cell volume
1019 density in testes of Controls and COVID-19 patients (t-test; two tailed; infected groups
1020 vs control; * p <0.05). h) measurement of intratesticular testosterone using RIA (t-test; two
1021 tailed; infected groups vs control; *** p <0.001; ** p <0.01). i-l) immunostaining for
1022 caspase 3, evidencing positive labeling in Leydig cells (green arrows) (Scale bars = 50
1023 μ m). i') Negative control (Scale bars = 50 μ m). m-n) TEM showing the presence of
1024 several electron-dense vacuoles in Leydig cell cytoplasm (white arrows) (Scale bars = m:
1025 2 μ m; n: 1 μ m). o-r) Trichrome Masson staining in the testis of Controls and COVID-19
1026 patients. In higher magnification, inserts (P1, P2, and P3) show the collagen deposition
1027 in the seminiferous tubules (Scale bars = 200 μ m). s-u) quantification of total collagen
1028 fibers, type I collagen, and type III collagen (t-test; two tailed; infected groups vs control;
1029 * p <0.05; COVID-19-P1 vs COVID-19-P2; # p <0.05). v) quantification of newly formed
1030 blood vessels (CD31+) (t-test; two tailed; infected groups vs control, * p <0.05). w)
1031 quantification of testicular hemorrhage (t-test; two tailed; infected groups vs control,
1032 * p <0.05). Testicular hemorrhage was classified as normal (x) and containing high
1033 numbers of red blood cells (arrows) in tubular and intertubular compartments (y), a vast
1034 number of red blood cells in the intertubular compartment (z), and few red blood cells in
1035 the intertubular compartment (α) (Scale bars = 50 μ m). P1, P2, P3: phase 1, 2, and 3

1036 COVID-19 patients, respectively. BV: blood vessels; IC: intertubular compartment; ST:
1037 seminiferous tubule cross-section.

1038



1039

1040


1041

1042 **Fig. 7. Hypothetical viral and molecular mechanisms of testis infection and**
1043 **damaging by SARS-CoV-2.** a) SARS-CoV-2 (green color) was identified in
1044 spermatogonial cells (Spg), Sertoli cells (SC), Leydig cells (LC), infiltrative monocytes
1045 (Mono), macrophages (MΦ), spermatocytes (sptc), and spermatids (sptd). Note viral
1046 factories in macrophages and spermatogonial cells (green arrows). Direct influence of
1047 SARS-CoV-2 in testicular cells hampers ACE2 activity, while activation of mast cells
1048 (chymase positive) elevates the levels of angiotensin II (a potent pro-inflammatory
1049 molecule) (asterisks). Angiogenic and inflammatory factors can induce the infiltration
1050 and activation of mast cells. High levels of angiotensin II, activation of mast cells, and
1051 inflammatory factors can activate (polarize) macrophages. The testicular phenotype of
1052 COVID-19 patients (fibrosis, vascular alteration, inflammation, tunica propria
1053 thickening, Sertoli cell barrier loss, germ cell apoptosis, and inhibition of Leydig cells)
1054 can be linked to elevated angiotensin II and active mast cells and macrophages. b) genes
1055 network related to angiotensin II, activated mast cells, and macrophages (pink box)
1056 extracted from STRING (<https://string-db.org/>). These three elements up-regulate the
1057 inflammatory, apoptotic, fibrotic, and vascular genes while down-regulating critical
1058 seminiferous tubule and Leydig cell genes. Red arrows: up-regulated genes; Green
1059 arrows: down-regulated genes; ~: genes up-and down-regulated depending on the phase.
1060
1061
1062
1063
1064
1065
1066
1067
1068


1069 SUPPLEMENTAL FIGURES

1070 Supplemental Figure 1

Recognition of S and N proteins



Limit of detection



Nano-sensor in testes of COVID-19 patients



1072 **Supplemental Fig. 1. COVID-19 nanosensor platforms.** Gold nanorods (GNRs) were
1073 coated with anti-S and anti-N antibodies to construct a COVID-19 nanosensor and then
1074 characterized by different techniques. a) UV-Vis LSPR spectra of bare GNRs, lipoic-acid
1075 coated surface (GNR-LA) and GNR nanosensors recognising S- and N-proteins,
1076 respectively. b) derivative curve of the observed light absorbance red shifts. c) TEM
1077 image of the GNRs. d) stability of both nanosensors by zeta potential measurements. e)
1078 the dynamic light scattering of both nanosensors and their respective hydrodynamic
1079 radius. f-g) fluorophores binding both nanosensors. h-k) Light absorbance spectra due to
1080 LSPR and respective derivative curves regarding the limits of detection of both
1081 nanosensors exposed to different concentrations of S- and N-proteins in means of nm
1082 shifting. m-p) Light absorbance spectra due to LSPR and respective derivative curves of
1083 the nanosensors recognising the presence of SARS-CoV-2 in each sample compared to
1084 non-infected Control. q) the LSPR shift (nm) of each nanosensor after samples exposure.
1085 (mean \pm SD, ****p<0.001)

1086

1087

1088

1089

1090


1091

1092

1093

1094

1095 **Supplemental Fig.2**



1096

1097

1098

1099 **Supplemental Fig. 2. Immunofluorescence against S-protein in testes of all COVID-**
1100 **19 patients.** a) mean fluorescence index (in pixels) evaluating the large images of
1101 immunostainings against S-protein. b-l) images of testis parenchyma of COVID-19
1102 patients. b-f) first phase COVID-19 patients. g-k) second phase COVID-19 patients. l)
1103 third phase COVID-19 patient. Inserts depict labeled germ cells in all patients. Scale bars
1104 = 20 μm . m-o) Controls of the immunofluorescence reactions. m) negative image of
1105 Control patient #1 (Scale bar = 70 μm). n) negative control, omitting the primary
1106 antibody. o-p) antigen control, comparing the tissue incubated with primary antibody (o)
1107 and primary antibody previously incubated with purified Spike protein.

1108

1109

1110

1111

1112

1113

1114

1115

1116


1117

1118

1119

1120

1121 **Supplemental Figure 3**



1122

1123

1124

1125

1126

1127

1128

1129

1130

1131

1132 **Supplemental Fig. 3. Histology of activated mast cells and infiltrative monocytes in**
1133 **COVID-19 patients.** a-b) activated mast cells (chymase +, white arrowheads) are not
1134 labeled for the S-protein (green). Blue = dapi staining. (Scale bars = 50 μ m). c) quantity
1135 of protein per milligram of tissue indicating an inflammatory process (t-test; two tailed;
1136 infected groups vs control, * $p < 0.05$). d-m) high number of mast cells in testes of COVID-
1137 19 patients (arrows) (Scale bar = 50 μ m). d-e) mast cells near blood vessels (BV) filled
1138 with immune cells (T represents a thrombotic area) (Scale bar = 20 μ m). f-g) perivascular
1139 mast cells (arrows) near intact (f) and disrupted (g) blood vessels (Scale bars = 15 μ m).
1140 h) mast cell (arrow) near Leydig cells (Scale bar = 15 μ m). i) mast cell (arrow) near
1141 thickened tunica propria (Scale bar = 15 μ m). j) mast cell (arrow) inside the seminiferous
1142 tubule (Scale bar = 15 μ m). k) mast cell (arrow) near a collagen matrix (Col) in the
1143 intertubular space (Scale bar = 15 μ m). l) mast cell (arrow) inside a fibrotic seminiferous
1144 tubule (Scale bar = 50 μ m). m) mast cell in the intertubular area of a third phase patient
1145 (Scale bar = 25 μ m). n-o) high number of infiltrative monocytes (red arrows) in the
1146 intertubular compartment (IC) (Scale bars = 20 μ m).

1147

1148

1149

1150


1151

1152

1153

1154

1155 **Supplemental Fig. 4**



1156

1157

1158

1159

1160

1161 **Supplemental Fig. 4. Tubular compartment morphological alterations.** a)
1162 quantification of the seminiferous tubule cross-sections profile (in %) in Controls and
1163 COVID-19 patients. b) seminiferous tubule diameter in Controls and COVID-19 patients
1164 (t-test; two tailed; infected groups vs control, * $p < 0.05$). c-d) high number of collagen
1165 fibers (asterisks) and peritubular myoid cells (My, white arrows) in COVID-19 patients
1166 (Scale bars = 2 μm). e-j) basement membrane (PAS+) in Controls (e-g) and COVID-19
1167 patients (h-j) (Scale bars = c: 30 μm). Asterisks denote high deposition of glycoproteins
1168 in the basement membrane and surrounding blood vessels. k-n) convoluted appearance
1169 of the basement membrane of COVID-19 patients (asterisks) (Scale bars = s: 1 μm ; t-v:
1170 10 μm). Mast cells (black arrows) and macrophages (green arrows) were observed near
1171 these areas. o) rete testis (RT) area filled with sloughing and apoptotic germ cells (green
1172 arrows) in COVID-19 patients (Scale bar = 50 μm). p-t) seminiferous epithelium
1173 detachment (black arrows) from the tunica propria in Controls and COVID-19 patients
1174 (t-test; two tailed; infected groups vs control, * $p < 0.05$) (Scale bars = 50 μm).

1175

1176

1177

1178

1179


1180

1181

1182

1183

1184 **Supplemental Fig. 5**



1185

1186

1187

1188

1189

1190

1191

1192

1193 **Supplemental Fig. 5. Leydig cell, collagen deposition, and blood vessel alterations in**
1194 **COVID-19 patients.** a-d) Leydig cell morphology in Controls and COVID-19 patients
1195 (Scale bars = 30 μm). b-d) vacuoles and granules in the Leydig cell cytoplasm. e-h)
1196 Picrossirius staining demonstrating Birefringence in Yellow Orange (type I collagen) and
1197 green (type III collagen) (Scale bars = 100 μm). i-k) CD31 immunolabeling in Controls
1198 (i) and COVID-19 patients (j-k) evidencing the newly formed blood vessels in testis
1199 parenchyma (Scale bar = 30 μm). l-m) blood vessels inside tunica propria (arrows) of
1200 COVID-19 patients (Scale bars = 30 μm). n) TEM image of an immature endothelial cell
1201 identified in tunica propria (Scale bar = 2 μm). o) red blood cells (arrows) inside the rete
1202 testis (RT) lumen (Scale bar = 30 μm). p) thrombus (*) inside the blood vessel (Scale bar
1203 = 30 μm). q-t) Endothelin1/2/3 immunolabeling in Controls (q) and COVID-19 phase
1204 one, phase two, and phase three (p1, p2, and p3) patients showing a higher intensity in
1205 phase one patients followed by weak labeling in phases two and three patients (Scale
1206 bars= 50 μm).

1207

1208

1209

1210

1211


1212

1213

1214

1215


1216



1217

1218 **Supplemental Fig 6. Transcript level of key genes related to high angiotensin II**
 1219 **levels, immune cells and vascular system and fibrosis.** a-c) Genes from the renin-
 1220 angiotensin system: ACE1 (a), ACE2 (b), and AGTR1 (c). d-e) mast cell genes: chymase
 1221 (CMA1) (d), and tryptase (TPSB2) (e). f) Histamine receptor (HRH4). g)
 1222 Cyclooxygenase-2 (COX-2). h) Monocyte chemoattractant protein 1 (MCP1). i) Vascular
 1223 Endothelial Growth Factor (VEGF). j) Platelet Derived Growth Factor (PDGF). k)
 1224 Transforming Growth Factor Beta 1 (TGFB1). l) Collagen Type III Alpha 1 Chain
 1225 (COL3A1). Data are expressed as geometric mean \pm SD. * $p < 0.05$ COVID-19 patients
 1226 compared to the Control group (which is set at 1; dashed line). # indicates significant
 1227 differences between COVID-19-P1 and COVID-19-P2 ($p < 0.05$); t-test (two-sided).

1228



1229

1230 **Supplemental Fig.7. Relative expression of important gene associated to the tubular**
 1231 **compartment and Leydig cells.** a) Deleted In Azoospermia Like (DAZL). b) BCL2
 1232 Associated X Protein (BAX). c) BCL2 Associated Agonist Of Cell Death (BAD). d)
 1233 Transmembrane Serine Protease 2 (TMPRSS2). e) Occludin (OCLN). f) GATA Binding
 1234 Protein 4 (GATA4). g) SRY-Box Transcription Factor 9 (SOX9). h) Actin, Alpha
 1235 Skeletal Muscle (aSMA). i-l) genes related to Leydig cell steroidogenesis: Luteinizing
 1236 Hormone Receptor (i), Steroidogenic Acute Regulatory Protein (j), 3 Beta-
 1237 Hydroxysteroid Dehydrogenase (k), Hydroxysteroid 17-Beta Dehydrogenase 3 (l). Data
 1238 are expressed as geometric mean \pm SD. * $p < 0.05$ COVID-19 patients compared to the
 1239 Control group (which is set at 1; dashed line). # indicates significant differences between
 1240 COVID-19-P1 and COVID-19-P2 ($p < 0.05$); t-test (two-sided).

1241

1242

1243

1244

1245

1247 Table 1- Clinical features of 11 COVID-19 patients

1248

| COVID-19 patient | Age range (years) | Body-weight (Kg) | BMI | Smoking habit | Comorbidities | Previous testicular disorder | Disease duration (days) | Hospital stay (days) | Body temp. (max) | Sign of Orchitis | Cause of death |
|------------------|-------------------|------------------|-------|---------------|--|------------------------------|-------------------------|----------------------|------------------|------------------|------------------------|
| #1 | 71-75 | 120 | 41.5 | Yes | SAH, Diabetes, Obesity | No | 26.00 | 21.0 | 38.7°C | No | multiple organ failure |
| #2 | 76-80 | 103 | 31.79 | No | SAH, Obesity | No | 32.00 | 25.0 | 37.9°C | No | septic shock |
| #3 | 56-60 | 100 | 32.65 | No | SAH, diabetes, Obesity | No | 31.00 | 20.0 | 38.4°C (>24hs) | No | septic shock |
| #4 | 56-60 | 80 | 26.12 | No | SAH, diabetes, Obesity, Hypothyroidism | No | 26.00 | 16.0 | 39.3° C (>24hs) | No | multiple organ failure |
| #5 | 86-90 | 88 | 30.4 | No | SAH, Diabetes, Hypothyroidism, CRI | No | 13.00 | 10.0 | 40.2°C | No | multiple organ failure |
| #6 | 76-80 | 85 | 29.41 | No | Hypothyroidism | No | 38.00 | 20.0 | 38.1°C | No | multiple organ failure |
| #7 | 46-50 | 100 | 34.6 | No | SAH, Obesity | No | 19.00 | 10.0 | 41.5° C (>24hs) | No | septic shock |
| #8 | 61-65 | 75 | 26.57 | No | SAH, Diabetes, Hypothyroidism, CRI | No | 18.00 | 11.0 | 38.4°C | No | multiple organ failure |
| #9 | 61-65 | 75 | 25.95 | No | SAH | No | 14.00 | 10.0 | 38.9°C (>24hs) | No | multiple organ failure |
| #10 | 51-55 | 130 | 44.46 | No | SAH, Diabetes, Obesity | No | 28.00 | 23.0 | 37.9°C (>24hs) | No | multiple organ failure |
| #11 | 46-50 | 99 | 30.56 | No | No | No | 16.00 | 8.0 | 40.9°C (>24hs) | No | multiple organ failure |

1249 Legends = BMI: body mass index; SAH: Systemic Arterial Hypertension; CRI: chronic renal insufficiency; temp.: temperature.

1250

1251

1252

1253

1254 **Table 2 – SARS-CoV-2 detection in testicular parenchyma**

1255

1256

1257

1258

1259

1260

1261

1262

1263

1264

1265

1266

1267

1268

1269

1270

| PATIENTS | Genetic evaluations | | | | Protein evaluations | | |
|------------------|---|--------------------------|--|-------------------------------------|------------------------------|------------------------------|----------------------------------|
| | SARS-CovV-2 E gene RT-qPCR (routinary diagnosis) (CT) | RNP control RT-qPCR (CT) | SARS-CoV-2 (N1) RT-qPCR (using viral primers) (CT) | β -actin control RT-qPCR (CT) | LSPR-nanosensor N shift (nm) | LSPR-nanosensor S shift (nm) | IF using anti-S protein (- or +) |
| CTRL #1 | - | 20 | - | 18.55 | 0 (-) | 0 (-) | - |
| CV-19 #1 | - | 23 | 32.78 (+) | 24.59 | 31.5 (+) | 51 (+) | + |
| CV-19 #2 | - | 27 | 36.99 (+) | 18.50 | 13.2 (+) | 18.9 (+) | + |
| CV-19 #3 | - | 22 | 36.34 (+) | 6.36 | 1.2 (-) | 17.5 (+) | + |
| CV-19 #4 | - | 20 | 35.96 (+) | 19.25 | 11.2 (+) | 17 (+) | + |
| CV-19 #5 | - | 20 | 36.14 (+) | 20.03 | 9.9 (+) | 20.9 (+) | + |
| CV-19 #6 | - | 21 | 36.22 (+) | 10.30 | 13.2 (+) | 15 (+) | + |
| CV-19 #7 | - | 20 | 35.37 (+) | 17.67 | 4.5 (-) | 12.4 (+) | + |
| CV-19 #8 | 38 (+) | 20 | 35.95 (+) | 19.34 | 17.5 (+) | 17 (+) | + |
| CV-19 #9 | - | 21 | - | 19.81 | 12.9 (+) | 17.5 (+) | + |
| CV-19 #10 | - | 23 | 34.03 (+) | 20.71 | 7.2 (+) | 13.6 (+) | + |
| CV-19 #11 | - | 23 | 35.65 (+) | 16.27 | 8.7 (+) | 16.5 (+) | + |

1271 Symbols = CV-19: COVID-19 patient; RNP: RNaseP gene; CT: cycle threshold; LSPR: localized surface plasmon resonance; IF:
 1272 immunofluorescence; (+) detection of viral content; (-) non-detection of viral content. Positivity in the RT-qPCR is detected when the CT is lower
 1273 than 40, and in the LSPR nanosensor is when the shift is higher than 5 nm.

1274
1275
1276

Supplemental Table 1. Clinical data from control patients.

| Control Patient | Age range | Fertility record (children) | FSH (mUI/ML) | LH (mUI/ML) | TTB (ng/dL) | Comorbidity |
|---------------------------|------------------|------------------------------------|---------------------|--------------------|--------------------|--------------------|
| #1 | 61-65 | Yes | 2.57 | 3.91 | 227 | Prostate cancer |
| #2 | 56-60 | Yes | 9.44 | 4.42 | 398 | Prostate cancer |
| #3 | 56-60 | Yes | 1.49 | 4.18 | 523 | Prostate cancer |
| #4 | 46-50 | Yes | 1.64 | 3.83 | 646 | Prostate cancer |
| #5 | 56-60 | Yes | 2.41 | 3.68 | 288 | Prostate cancer |
| #6 | 61-65 | Yes | 2.38 | 9.40 | 267 | Prostate cancer |
| Value of Reference | - | - | 1.55-9.74 | 0.82-6.22 | 71.8-623 | - |

1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291

1292

1293 **Supplemental Table 2** – Antibodies and Primers (qPCR) used in this study.

| Antibodies | Type | Species | Source | Id | Dilution |
|--|----------------------------------|---------|------------------------|-----------|----------|
| 3βHSD | Polyclonal | Goat | Santa Cruz Biotech. | sc-30820 | 1:100 |
| AGT1R | Polyclonal | Rabbit | Rhea Biotech | IM-0064 | 1:50 |
| Anti- Protein S COVID-19 | Monoclonal | Rabbit | Rhea Biotech | IM-0828 | 1:50 |
| Caspase 3 | Polyclonal | Rabbit | Imuny | IM0035 | 1:100 |
| Caspase 8 | Polyclonal | Mouse | Cell Signaling | Asp 387 | 1:100 |
| CD68 | Monoclonal | Mouse | Abcam | ab955 | 1:20 |
| ECA2 | Monoclonal | Mouse | Proteintech | AG15554 | 1:100 |
| Endotelin | Polyclonal | Rabbit | Santa Cruz Biotech. | sc-98727 | 1:100 |
| Mast Cell Chymase | Polyclonal | Goat | Santa Cruz Biotech. | sc-324924 | 1:100 |
| TLR2 | Polyclonal | Rabbit | Rhea Biotech | IM-0071 | 1:100 |
| UTF1 | Monoclonal | Mouse | EMD Millipore Corp. | Mab4337 | 1:100 |
| Goat anti-rabbit (IgG-CFL 488) | Secondary | Goat | Santa Cruz Biotech. | sc-362262 | 1:200 |
| Goat anti-mouse (IgG- 546) | Secondary | Goat | Invitrogen | A-11003 | 1:200 |
| Rabbit anti-goat (Cy3) | Secondary | Rabbit | Sigma | c2821 | 1:200 |
| Goat anti-mouse (IgG-594) | Secondary | Goat | Jackson Immunoresearch | 156816 | 1:100 |
| Gene | Sequence Of Primer (5'-3') | | | | |
| 3BHSD | F: CACATGGCCCGCTCCATAC | | | | |
| <i>3β-Hydroxysteroid Dehydrogenase</i> | R: GTGCCGCCGTTTTTCAGATTC | | | | |
| ACE1 | F: CCA CGT CCC GGA AAT ATG AAG | | | | |
| <i>Angiotensin I Converting Enzyme</i> | R: AGT CCC CTG CAT CTA CAT AGC | | | | |
| ACE2 | F: CAA GAG CAA ACG GTT GAA CAC | | | | |
| <i>Angiotensin-Converting Enzyme 2</i> | R: CCA GAG CCT CTC ATT GTA GTC T | | | | |
| AGTR1 | F: ATTTAGCACTGGCTGACTTATGC | | | | |
| <i>Angiotensin II Receptor Type 1</i> | R: CAGCGGTATTCCATAGCTGTG | | | | |
| aSMA | F: CCC AGC CAA GCA CTG TCA | | | | |
| <i>α-Smooth Muscle Actin</i> | R: TCC AGA GTC CAG CAC GAT G | | | | |
| BAD | F: CCC AGA GTT TGA GCC GAG TG | | | | |
| <i>BCL2 Associated Agonist of Cell Death</i> | R: CCC ATC CCT TCG TCG TCC T | | | | |
| BAX | F: GAT GCG TCC ACC AAG AAG C | | | | |
| <i>BCL2-associated X protein</i> | R: CCA GTT GAA GTT GCC GTC AG | | | | |
| CASP3 | F: GAC TGT GGC ATT GAG ACA GAC | | | | |
| <i>Caspase-3</i> | R: CTT TCG GTT AAC CCG GGT AAG | | | | |
| CLDN11 | F: CGGTGTGGCTAAGTACAGGC | | | | |
| <i>Claudin 11</i> | R: CGCAGTGTAGTAGAAACGGTTTT | | | | |
| CMA1 | F: GGCTTCAACACACCTGTTCTT | | | | |

| | |
|---|--|
| <i>Chymase 1</i> | R: TGGAAAACCCACATTTGTGACGC |
| COX2 | F: CTGGCGCTCAGCCATACAG |
| <i>Cyclooxygenase-2</i> | R: CGCACTTATACTGGTCAAATCCC |
| CX43 | F: GGT CTG AGT GCC TGA ACT TGC CT |
| <i>Connexin 43</i> | R: TGC CTG GGC ACC ACT CTT TTG C |
| DAZL | F: GCCACAACCACGATGAATC |
| <i>Deleted in azoospermia-like</i> | R: CGGAGGTACAACATAGCTCCTTT |
| GATA4 | F: CCT GGC CTG TCA TCT CAC TAC |
| <i>GATA Binding Protein 4</i> | R: AGA GGA CAG GGT GGA TGG A |
| HPRT1 | F: CCT GGC GTC GTG ATT AGT GAT |
| <i>Hypoxanthine Phosphoribosyltransferase 1</i> | R: AGA CGT TCA GTC CTG TCC ATA A |
| HRH4 | F: TGGGCCAATGATTCTAGTTTCAG |
| <i>Histamine Receptor H4</i> | R: ACTAAGATGACTGGGATCACGAA |
| HSD17B3 | F: CCC ATC TAT TCG GTT CGT ATG GGC |
| <i>17β-Hydroxysteroid Dehydrogenase 3</i> | R: GCC AGA GTC AGC GAA GGC GA |
| LHR | F: GCT GTG CTT TTA GAA ACT TGC CAA CAA |
| <i>Luteinizing Hormone Receptor</i> | R: TTC ATA GTC CCA GCC ACT CAG TTC ACT |
| MCP1 | F: GTG TTC AAG TCT TCG GAG TT |
| <i>Monocyte Chemoattractant Protein-1</i> | R: CAA TAG GAA GAT CTC AGT GC |
| OCLN | F: ACAAGCGGTTTTATCCAGAGTC |
| <i>Occludin</i> | R: GTCATCCACAGGCGAAGTTAAT |
| PDGF | F: GCT GCT GCA ACA CGA GCA GT |
| <i>Platelet-derived growth factor</i> | R: CCG GAT TCA GGC TTG TGG TC |
| RPL19 | F: GCG GGC CAA GGT GTT TTT C |
| <i>Ribosomal Protein L19</i> | R: TCG CCT CTA GTG TCC TCC G |
| SOX9 | F: GAC TTC CGC GAC GTG GAC |
| <i>SRY-Box Transcription Factor 9</i> | R: GTT GGG CGG CAG GTA CTG |
| STAR | F: GGGAGTGGAACCCCAATGTC |
| <i>Steroidogenic Acute Regulatory Protein</i> | R: CCAGCTCGTGAGTAATGAATGT |
| TGFB1 | F: CTA ATG GTG GAA ACC CAC AAC G |
| <i>Transforming growth factor beta 1</i> | R: TAT CGC CAG GAA TTG TTG CTG |
| TMPRSS2 | F: ACTCTGGAAGTTCATGGGCAG |
| <i>Transmembrane Serine Protease 2</i> | R: TGAAGTTTGGTCCGTAGAGGC |
| TRPB2 | F: TGGAAAACCCACATTTGTGACGC |
| <i>Tryptophan synthase beta chain 2</i> | R: GACACGGGTGTAGATGCCA |
| VEGF | F: CAC CCA TGG CAG AAG GAG GA |
| <i>Vascular endothelial growth factor</i> | R: ACT CCA GGC CCT CGT CAT TG |

1294

1295